Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease
Overview
- Phase
- Phase 4
- Intervention
- Sitagliptin and acarbose
- Conditions
- Newly Diagnosed Type 2 Diabetes
- Sponsor
- Wuhan General Hospital of Guangzhou Military Command
- Enrollment
- 66
- Locations
- 2
- Primary Endpoint
- Left ventricular mass and left ventricular volume
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
Cardiovascular complications account for the highest mortality in type 2 diabetic patients, mainly due to coronary artery disease (CAD).Left ventricular hypertrophy (LVH) is widespread in type 2 diabetic patients with CAD, even in the absence of hypertension .It is a strong predictor of cardiovascular events and all-cause mortality .
Sitagliptin, an inhibitor of dipeptidyl peptidase-4 (DPP-4), may regress left ventricular mass (LVM) in newly diagnosed type 2 diabetic patients with CAD .
Investigators
Xiang Guang-da
director
Wuhan General Hospital of Guangzhou Military Command
Eligibility Criteria
Inclusion Criteria
- •Patients had to have the levels of hemoglobin A1c (HbA1c) \> 7.0 %. They also had to have either angiographically documented coronary artery disease or a previous history of myocardial infarction. In addition, they were also required to have an office BP \< 135/85 mm Hg and the presence of LVH on echocardiography (American Society of Echocardiography criteria LVM index \[LVMI\] \> 115 g/m2 for men and \> 95 g/m2 for women) . -
Exclusion Criteria
- •Patients were excluded if they were currently prescribed glucagon-like peptide (GLP) -1 analogues or DPP-4 inhibitors or glucosidase inhibitor or anti-hypertensive drugs (including b-blockers), diabetes medications, estrogen supplements, thyroxine, diuretics, hypolipidemic drugs. They were also excluded if they had renal and liver dysfunction, heart failure, or malignancy, or were unable to give informed consent. Patients with contraindications to cardiac magnetic resonance (CMR) (pacemakers, claustrophobia) were also excluded, as were pregnant or lactating women. -
Arms & Interventions
Sitagliptin
Sitagliptin 0.1 daily for 1 year
Intervention: Sitagliptin and acarbose
acarbose
acarbose 150mg daily for 1 year
Intervention: Sitagliptin and acarbose
Outcomes
Primary Outcomes
Left ventricular mass and left ventricular volume
Time Frame: 2013~2014(follow up 1 year)
Cardiac magnetic resonance (CMR) imaging was performed at baseline and at 12 months for left ventricular mass and left ventricular volume.
Secondary Outcomes
- Endothelial function and augmentation index (AIx)(2013~2014 (follow up 1 year))